All In Biotech

Drug Trial Radar · NCT02813694

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia

Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 738 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

738

Actual

Start

Aug 2016

Primary completion

Jan 2018

Study completion Jan 2018

Sponsor

Lead sponsor
Nabriva Therapeutics AGIndustry
Sponsor type
Industry
First posted
Jun 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia

Conditions

  • Community Acquired Pneumonia

Interventions

  • lefamulinDrug

    antibacterial agent

  • MoxifloxacinDrug

    antibacterial agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical Response (ECR)Time frame: 96 hours +/- 24 hours after first dose of study drug

Locations

155 sites in 20 countries. Site status is shown where the registry gives one.

  • 1080

    Beverly Hills, California

  • Site 1065

    Fresno, California

  • 1078

    Northridge, California

  • Site 1072

    Oxnard, California

  • Site 1070

    Sacramento, California

  • 1079

    Sherman Oaks, California

  • Site 1053

    Sylmar, California

  • Site 1064

    DeBary, Florida

  • Site 1052

    DeLand, Florida

  • 1076

    Miami, Florida

  • Site 1051

    Michigan City, Indiana

  • Site 1057

    Natchitoches, Louisiana

  • Site 1073

    New Bedford, Massachusetts

  • Site 1055

    Detroit, Michigan

  • Site 1062

    Detroit, Michigan

  • Site 1068

    Royal Oak, Michigan

  • Site 1058

    St Louis, Missouri

  • Site 1054

    Butte, Montana

  • Site 1067

    Lima, Ohio

  • Site 1056

    Rapid City, South Dakota

  • 1077

    Hendersonville, Tennessee

  • Site 1060

    Houston, Texas

  • Site 1069

    Houston, Texas

  • Site 1066

    Splendora, Texas

  • Site 1059

    Charlottesville, Virginia

  • Site 3056

    Buenos Aires, Argentina

  • Site 3059

    Buenos Aires AV, Argentina

  • Site 3054

    Córdoba, Argentina

  • Site 3052

    Córdoba, Argentina

  • Site 3057

    Córdoba, Argentina

  • Site 3058

    General Pacheco, Argentina

  • Site 3051

    La Plata, Argentina

  • Site 3053

    La Plata, Argentina

  • Site 3154

    Belo Horizonte, Brazil

  • Site 3153

    Passo Fundo, Brazil

  • Site 3152

    São José do Rio Preto, Brazil

  • 4162

    Rousse, Bulgaria

  • Site 4154

    Sliven, Bulgaria

  • Site 4160

    Sofia, Bulgaria

  • Site 4157

    Sofia, Bulgaria

Showing 40 of 155 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.